arrow
K

Kentaro Ito

Wakayama Medical University
H指数:17
被引数:1,168

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
2024-04-133
OAAI
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis

尼达尼布联合化疗治疗小细胞肺癌合并特发性肺纤维化

2024-04-014
PRE
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
2024-01-015
OA
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
2023-12-011
OA
Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial

非小细胞肺癌 (SCORPION) 一线铂类化疗加免疫检查点抑制剂后多西他赛加雷莫昔单抗二线治疗的疗效和安全性: 一项多中心、开放标签、单臂、2期临床试验

2023-12-014
OAAI
Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions
2023-09-071
OAAI
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
2023-09-011
PRE
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

晚期非小细胞肺癌中基于铂类化疗联合程序性死亡-1阻滞后ramucirumab联合多西他赛的多中心真实数据: NEJ051 (反应性研究)

2023-05-0110
PRE
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
2023-03-063
OAAI
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

EGFR突变型NSCLC患者奥希替尼治疗后基于免疫检查点抑制剂的治疗的真实世界分析

2022-09-018
OA